Filing Analysis
Veru Inc. filed an 8-K to announce its quarterly and nine-month financial results for the period ending June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 10, 2026.
📋 Key Facts
- Reporting period: Quarter and nine months ended June 30, 2026.
- Filing date: August 10, 2026.
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Veru Inc. entered into an 'at-the-market' (ATM) sales agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC to facilitate the potential sale of up to $21.8 million in common stock.
🚩 Red Flags
- Potential for significant shareholder dilution via the ATM offering.
📋 Key Facts
- Entered into a Sales Agreement on July 2, 2026.
- The offering is for up to $21,800,000 of Common Stock.
- Sales Agents: Oppenheimer & Co. Inc. and Canaccord Genuity LLC.
- Selling method: 'At the market' (ATM) offering under Rule 415(a)(4).
- Commission rate: 3.0% of aggregate gross proceeds.
- The offering is registered under a previously effective Form S-3 (File No. 333-294911).
Veru Inc. entered into a clinical supply agreement with Novo Nordisk A/S on June 2, 2026, for the Phase 2b PLATEAU clinical study. Novo Nordisk will provide Wegovy® at no charge for the study in exchange for clinical insights and a right of first negotiation for future combined commercialization.
🚩 Red Flags
- The 'Forward-Looking Statements' section explicitly mentions the company's need to obtain financing to 'enable us to continue as a going concern'.
- The Supply Agreement can be terminated by Novo Nordisk for convenience upon 60 days' prior notice.
📋 Key Facts
- Agreement date: June 2, 2026.
- Novo Nordisk will supply Wegovy® (semaglutide) at no charge for the Phase 2b PLATEAU study.
- Veru is solely responsible for conducting and sponsoring the study.
- Veru granted Novo Nordisk a 'right of first negotiation' for future development or licensing of enobosarm in combination with Novo Nordisk GLP-1 products.
- Veru retains full global development and commercialization rights to enobosarm.
Veru Inc. reported its financial results for the fiscal second quarter and six months ended March 31, 2026. The information was furnished via a press release as part of a routine quarterly earnings disclosure.
📋 Key Facts
- Filing date: May 13, 2026
- Reporting period: Fiscal quarter and six months ended March 31, 2026
- Disclosed under Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains the full earnings press release
Veru Inc. reported the results of its 2026 Annual Meeting, where shareholders approved a significant expansion of the 2018 Equity Incentive Plan. The amendment more than doubles the authorized shares for issuance and substantially increases individual award limits for both employees and directors.
🚩 Red Flags
- Significant potential dilution: The 125% increase in authorized shares for the equity plan (3.25 million additional shares) is substantial for a micro-cap company.
- The annual limit for awards to non-employee directors was increased 12-fold from 10,000 to 120,000 shares.
📋 Key Facts
- Authorized shares in the 2018 Equity Incentive Plan increased from 2,600,000 to 5,850,000 shares.
- Annual award limit for participants other than non-employee directors increased from 100,000 to 750,000 shares.
- Annual award limit for non-employee directors increased from 10,000 to 120,000 shares.
- Shareholders ratified Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
- All six director nominees, including CEO Mitchell S. Steiner, were re-elected to the Board.
Veru Inc. filed an 8-K to announce its quarterly results for the period ended December 31, 2025. The filing serves as a formal notification that financial results have been released via press release.
📋 Key Facts
- Report date: February 11, 2026
- Reporting period: Quarter ended December 31, 2025
- The company issued a press release (Exhibit 99.1) containing the results.
- Filed under Item 2.02 regarding Results of Operations and Financial Condition.
Veru Inc. filed an 8-K to announce its results of operations and financial condition for the fiscal year ended September 30, 2025.
📋 Key Facts
- The filing reports on results for the fiscal year ended September 30, 2025.
- The announcement was made via a press release dated December 17, 2025.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
Veru Inc. entered into an underwriting agreement to conduct a public offering of 8.4 million shares (or pre-funded warrants) and accompanying Series A and B warrants at $3.00 per share. The offering aims to raise approximately $23.4 million in net proceeds.
🚩 Red Flags
- Significant dilution potential due to the issuance of up to 8.4 million warrants alongside common stock.
- Use of pre-funded warrants suggests a need to accommodate institutional investors with ownership restrictions (4.99%/9.99%).
- Series B Warrants are tied to specific clinical trial outcomes, indicating high dependency on Phase 2b PLATEAU study data.
📋 Key Facts
- Offering size: 8,400,000 shares of common stock or pre-funded warrants.
- Combined public offering price: $3.00 per share and accompanying Series A/B Warrants.
- Expected net proceeds: Approximately $23.4 million after discounts and expenses.
- Series B Warrants expire upon the earlier of 3 years or specific clinical data milestones (Phase 2b PLATEAU study) + stock price condition ($4.00 for 10 days).
- Underwriter: Canaccord Genuity LLC.
- Expected closing date: On or about October 31, 2025.
Veru Inc. has entered into a Settlement Agreement with Onconetix, Inc. to resolve outstanding debt obligations totaling $8,826,155.41. The settlement involves receiving cash, preferred stock, and warrants in lieu of the full cash amount owed.
🚩 Red Flags
- Significant haircut on cash principal: The company accepted ~$6.3M in cash for an $8.8M debt, representing a ~27% reduction in total value if the equity/warrants are valued at zero.
- Complexity of recovery: A significant portion of the settlement is tied to illiquid or speculative assets (Convertible Preferred Stock and Warrants) rather than cash.
📋 Key Facts
- Total amount payable under Promissory Notes as of Sept 22, 2025: $8,826,155.41
- Settlement Amount received: $6,326,155.41 in cash, 3,125 shares of Series D Convertible Preferred Stock (stated value $1,000/share), and 846,975 warrants.
- The settlement fully discharges all obligations under the April 2024 and September 2024 Promissory Notes.
- Settlement was executed on September 22, 2025; payment received by September 24, 2025.
Veru Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This resolves the delisting risk that had been pending since August 2024.
🚩 Red Flags
- Historical volatility: The company has been struggling with minimum bid price requirements for over a year (since Aug 2024).
📋 Key Facts
- Nasdaq confirmed on August 26, 2025, that Veru Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The minimum bid price matter is now officially closed.
- Compliance was achieved following a deadline extension to August 25, 2025.
- The original non-compliance notice was issued on August 29, 2024.
Veru Inc. has implemented a 1-for-10 reverse stock split effective August 8, 2025, following shareholder approval on July 25, 2025. The split aims to adjust the share price and maintains trading on the Nasdaq Capital Market under the same symbol 'VERU'.
🚩 Red Flags
- Reverse stock split (often used to avoid delisting or to improve share price perception).
- Significant reduction in share count which can lead to increased volatility and dilution concerns if not paired with fundamental improvements.
📋 Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective Date/Time: August 8, 2025, at 11:59 pm CT.
- Trading resumption: Expected on or about August 11, 2025, on a split-adjusted basis.
- New CUSIP number: 92536C202.
- Fractional shares will be settled in cash; no fractional shares will be issued.
- The split affects all outstanding equity awards under the company's various incentive plans proportionally.
Veru Inc. filed an 8-K to announce its quarterly and nine-month financial results for the period ending June 30, 2025.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter and nine months ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Veru Inc. shareholders approved a proposal for a reverse stock split at a ratio between 1-for-2 and 1-for-20 during a special meeting held on July 25, 2025. The vote was overwhelmingly in favor of the amendment to the company's Articles of Incorporation.
🚩 Red Flags
- Approval of a reverse stock split is often used to combat low share prices and prevent delisting from exchanges like NASDAQ.
- The wide range (1-for-2 to 1-for-20) indicates significant uncertainty regarding the final impact on equity structure.
📋 Key Facts
- Special Meeting held on July 25, 2025.
- Total shares eligible to vote: 146,583,920.
- Shareholders approved a reverse stock split ratio range of 1-for-2 to 1-for-20.
- The specific ratio will be determined by the Board of Directors.
- Votes for Reverse Split: 98,869,209; Votes Against: 7,080,957.
Veru Inc. filed an 8-K to announce its financial results for the quarter and six months ended March 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on May 8, 2025.
📋 Key Facts
- Reporting period: Quarter and six months ended March 31, 2025.
- Announcement date: May 8, 2025.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Veru Inc. reported the results of its Annual Meeting of Shareholders held on March 13, 2025. The meeting included the election of directors, ratification of auditors, and approval to amend the company's Equity Incentive Plan.
📋 Key Facts
- Shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing authorized shares from 18,500,000 to 26,000,000.
- All six nominated directors were elected to the Board of Directors: Mitchell S. Steiner, Harry Fisch, Michael L. Rankowitz, Grace Hyun, Lucy Lu, and Loren Katzovitz.
- Shareholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025.
- Total shares eligible to vote at the meeting: 146,383,920.
Veru Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The company explicitly stated it may implement a reverse stock split to satisfy this requirement.
🚩 Red Flags
- Delisting risk: Failure to meet the new deadline will lead to delisting proceedings.
- Reverse stock split: The company has signaled it may undergo a reverse split, which often results in significant shareholder dilution or negative market sentiment.
- Persistent non-compliance: This is an extension of an existing deficiency dating back to August 2024.
📋 Key Facts
- Nasdaq granted an extension until August 25, 2025, to resolve the minimum bid price deficiency.
- The original compliance deadline was February 25, 2025.
- Compliance requires a closing bid price of at least $1.00 for ten consecutive business days.
- Management explicitly mentioned that a reverse stock split is being considered as a potential remedy.
Veru Inc. filed an 8-K to announce its quarterly results for the period ending December 31, 2024.
📋 Key Facts
- Report date: February 13, 2025
- Reporting period: Quarter ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Veru Inc. has completed the sale of substantially all assets related to its FC2 female condom business to Clear Future, Inc. for a total purchase price of $18.0 million in cash.
🚩 Red Flags
- Significant divestiture of a business unit (FC2) may indicate a strategic pivot or a need for liquidity to fund core R&D/operations.
- The company is paying out a significant portion ($4.2M) of the gross proceeds to settle a royalty obligation.
📋 Key Facts
- Transaction closed on December 30, 2024.
- Total purchase price is $18.0 million in cash, subject to working capital adjustments.
- Estimated net proceeds to Veru Inc. are approximately $12.5 million after deducting a $4.2 million change of control payment and transaction fees.
- The sale includes the stock of the Company's U.K. and Malaysian operating subsidiaries.
- The Royalty Agreement with SWK Funding LLC was terminated upon the $4.2 million payment.
Veru Inc. has entered into an Amended and Restated Forbearance Agreement with Onconetix, Inc. (formerly Blue Water Vaccines Inc.) regarding two promissory notes totaling $10 million. The agreement extends maturity dates and increases the percentage of cash receipts/financing proceeds required to service the debt.
🚩 Red Flags
- The borrower (Onconetix) has already defaulted on previous payment obligations.
- Increased percentage of cash receipts/financing proceeds required suggests heightened risk in the borrower's ability to repay.
- Uncertainty expressed regarding whether Veru will ever receive any payments from the Borrower.
📋 Key Facts
- Amended Forbearance Agreement signed on September 19, 2024.
- Relates to two promissory notes: April 2024 Note ($5M) and September 2024 Note ($5M).
- April 2024 Note forbearance extended until March 31, 2025, or an Event of Default.
- September 2024 Note maturity date extended to June 30, 2025.
- Required payments from Borrower increased: monthly cash receipts (from licensing/sales) requirement raised from 15% to 25%; net proceeds from financing raised from 10% to 20%.
- Interest rate on September 2024 Note set at 10% per annum starting October 1, 2024.
- Incentive: If all debt is repaid in cash by December 31, 2024, the September 2024 Note principal requirement drops from $5M to $3.5M.
Veru Inc. received a notification from Nasdaq stating it is non-compliant with the minimum $1.00 closing bid price requirement after trading below that level for 30 consecutive business days. The company has until February 25, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement.
- Potential for a mandatory reverse stock split to regain compliance in the future.
- Persistent downward pressure on share price (30 consecutive business days below $1.00).
📋 Key Facts
- Received Nasdaq notification on August 29, 2024.
- Non-compliance due to failure to maintain a minimum closing bid price of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- The deficiency was triggered by the stock closing below $1.00 for 30 consecutive business days.
- The company has an initial 180-day grace period to regain compliance, expiring February 25, 2025.
- Compliance can be achieved if the bid price closes at or above $1.00 for at least 10 consecutive trading days.
- A second 180-day extension may be available if certain market value requirements are met and a reverse stock split is utilized.
Veru Inc. has terminated its Open Market Sales Agreement with Jefferies LLC, effective September 3, 2024. The termination prevents the company from issuing further shares under this specific $75 million program.
🚩 Red Flags
- The company has only realized $1.1 million in net proceeds despite a $75 million ceiling, suggesting limited effectiveness or strategic shift in capital raising.
📋 Key Facts
- Termination of Open Market Sales Agreement dated May 12, 2023.
- Effective date of termination: September 3, 2024.
- The agreement allowed for the sale of common stock up to an aggregate value of $75 million.
- Total shares sold under this agreement to date: 1,367,415 shares.
- Net proceeds generated from previous sales: $1.1 million.
- No termination penalties apply to Veru Inc.
Veru Inc. filed an 8-K to announce its quarterly and nine-month financial results for the period ending June 30, 2024.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter and nine months ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
Veru Inc. announced the expansion of its Board of Directors from six to seven members with the appointment of Loren Mark Katzovitz. Mr. Katzovitz will serve on both the Audit and Compensation Committees.
📋 Key Facts
- Board size increased from 6 to 7 directors.
- Loren Mark Katzovitz appointed as a new director effective August 1, 2024.
- Mr. Katzovitz appointed to the Board's Audit Committee and Compensation Committee.
- The Board has determined Mr. Katzovitz is 'independent' per NASDAQ listing standards.
Veru Inc. reconvened its 2024 Annual Meeting of Shareholders on June 27, 2024, to elect members to the Board of Directors. All nominated directors were successfully elected by the shareholders.
🚩 Red Flags
- The meeting had to be adjourned from its original date (June 18), which can sometimes indicate proxy solicitation issues or lack of quorum, though a quorum was achieved at the reconvened meeting.
📋 Key Facts
- Reconvened Annual Meeting held on June 27, 2024 (previously adjourned on June 18, 2024).
- Total shares eligible to vote: 146,381,186.
- Quorum established with 77,933,668 shares present or represented by proxy.
- Six directors were elected: Mitchell S. Steiner, Mario Eisenberger, Harry Fisch, Lucy Lu, Michael L. Rankowitz, and Grace Hyun.
Veru Inc. failed to reach a quorum at its 2024 Annual Meeting of Shareholders on June 18, 2024. Consequently, shareholders voted to adjourn the meeting to June 27, 2024, specifically to allow for further proxy solicitation to achieve a required majority.
🚩 Red Flags
- Failure to achieve quorum indicates potential shareholder apathy or lack of engagement with company governance.
- The need for 'further solicitation of proxies' suggests the company is struggling to secure enough votes to conduct official business, which can be a precursor to governance issues.
📋 Key Facts
- Annual Meeting held on June 18, 2024, failed to reach a quorum.
- Total shares eligible to vote: 146,381,186.
- Shares present/represented: 72,634,840 (approximately 49.6% of eligible shares).
- Quorum requirement: 73,190,594 shares (a majority of outstanding/eligible shares).
- Shareholders approved the adjournment proposal with 57,376,143 votes in favor.
- Meeting adjourned to Thursday, June 27, 2024, at 9:00 a.m. local time.
Veru Inc. has dismissed its independent auditor, RSM US LLP, and appointed Cherry Bekaert LLP. The dismissal follows a period of material weaknesses in internal controls over financial reporting and previous restatements.
🚩 Red Flags
- Auditor change combined with previous restatements (Red Flag Escalator).
- Presence of 'substantial doubt' regarding going concern in recent audit reports.
- Multiple material weaknesses in internal controls over financial reporting (ICFR) identified in 2023 and 2024.
- History of restating previously issued consolidated financial statements.
📋 Key Facts
- Dismissed RSM US LLP on May 16, 2024; engaged Cherry Bekaert LLP on May 21, 2024.
- The fiscal year ended September 30, 2023 report included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- A material weakness in internal control over financial reporting was identified related to technical accounting guidance for nonrecurring events (disclosed Nov 15, 2023).
- A second material weakness was identified regarding management review controls over R&D expense estimates (disclosed April 1, 2024).
- The company has undergone restatements of financial statements for the years ended 2022 and 2023 due to these internal control failures.
Veru Inc. filed an 8-K to announce its quarterly and semi-annual financial results for the period ending March 31, 2024.
📋 Key Facts
- Report date: May 8, 2024
- Reporting period: Quarter and six months ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
Veru Inc. entered into a Forbearance Agreement with Onconetix, Inc. (formerly Blue Water Vaccines Inc.) following defaults on two $5 million promissory notes. The agreement provides temporary relief for the borrower but leaves significant principal amounts due in the near term.
🚩 Red Flags
- Default on existing debt obligations by a counterparty (Onconetix).
- Significant upcoming maturity: A full $5,000,000 principal payment is due on September 30, 2024.
- Uncertainty regarding recovery of funds: Company explicitly states there is 'no assurance' as to whether/when payments will be received.
📋 Key Facts
- On April 24, 2024, Veru entered a Forbearance Agreement with Onconetix, Inc. regarding defaults on two $5M promissory notes (due April 19, 2024, and September 30, 2024).
- The borrower must make a $50,000 principal payment by April 29, 2024.
- Forbearance period lasts until March 31, 2025, or an Event of Default occurs.
- Borrower agreed to pay Veru monthly payments equal to 15% of cash receipts from certain sale/licensing revenues during the forbearance period.
- The September 30, 2024, maturity date for the second $5M note remains unchanged and is not subject to this forbearance.
Veru Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement. This follows a period of non-compliance where the stock's average closing bid price fell below $1.00.
🚩 Red Flags
- Historical delisting risk (though now resolved)
📋 Key Facts
- Nasdaq confirmed on April 23, 2024, that Veru Inc. has regained compliance with Listing Rule 5550(a)(2).
- The non-compliance was due to the average closing bid price being below $1.00 over 30 consecutive business days.
- Compliance status was previously reported as a risk on January 26, 2024.
Veru Inc. received a notice from Nasdaq indicating non-compliance with continued listing requirements due to a delay in filing its Form 10-Q for the quarter ended December 31, 2023. The company has until April 22, 2024, to submit a plan to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq due to failure to meet timely filing requirements.
- Potential for trading suspension if compliance plan is not accepted or milestones are missed.
📋 Key Facts
- Received notice from Nasdaq Listing Qualifications Department on February 21, 2024.
- Non-compliance is due to delay in filing the Quarterly Report (Form 10-Q) for the period ending December 31, 2023.
- The company has 60 days from the notice date (until April 22, 2024) to submit a compliance plan.
- If a plan is accepted, Nasdaq may grant up to 180 additional days (until August 19, 2024) to file the delinquent report.
Veru Inc. has determined that its consolidated financial statements for the fiscal year ended September 30, 2023, should no longer be relied upon due to errors in estimating research and development expenses. The error resulted in an overestimation of R&D costs, which implies a higher-than-reported cash position than previously stated.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02).
- Potential material weaknesses in internal controls over financial reporting.
- Risk of delayed SEC filings which could impact eligibility to use Form S-3.
- Potential for regulatory investigations or sanctions by the SEC.
📋 Key Facts
- The Audit Committee concluded on February 15, 2024, that prior financial statements for the year ended September 30, 2023, are unreliable.
- Error cause: Overestimation of R&D expenses related to third-party service providers due to inaccuracies in work completion estimates and contract provisions.
- Financial impact: The company's cash on hand is expected to be higher than initially reported because expenses were recorded at too high an amount.
- Scope of review: The company is evaluating the impact on fiscal year 2022 audited statements and unaudited quarterly statements for 2022 and 2023.
Veru Inc. filed an 8-K to announce its quarterly financial highlights for the period ending December 31, 2023. The filing serves as a formal notification that results of operations and financial condition data have been released via press release.
📋 Key Facts
- Reporting date: February 8, 2024
- Period covered: Quarter ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial highlights.
- The information is furnished under Item 2.02 and not 'filed' for purposes of Section 18.
Veru Inc. received a notification from Nasdaq stating it is non-compliant with the minimum $1.00 closing bid price requirement after trading below that level for 30 consecutive business days. The company has until July 23, 2024, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential for mandatory reverse stock split to regain compliance
- Sustained period of low share price (30 consecutive business days)
📋 Key Facts
- Received Nasdaq notification on January 25, 2024.
- Non-compliance due to failure to maintain a minimum closing bid price of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- The deficiency was triggered by the stock trading below $1.00 for 30 consecutive business days.
- The company has a primary compliance period of 180 calendar days, expiring July 23, 2024.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive trading days.
- A second 180-day extension may be available if certain market value requirements are met and a reverse stock split is planned/executed.